Wednesday, 14 October 2015
AstraZeneca is proud to support a new Insight by Nature on precision medicine. Currently, 80% of our pipeline takes a precision medicine, or personalised healthcare, approach.
AstraZeneca is proud to support a Nature Insight describing advances in precision medicine. Precision medicine, or personalised healthcare, is an integral part of our approach to discovering and developing new medicines; we see this as the future of healthcare for patients and providers alike. This approach offers us the opportunity to identify novel disease targets, enrich clinical trials and demonstrate clear value to payers. Most importantly, it increases our ability to make the right medicines for the different groups of patients who will benefit from them most. For AstraZeneca, precision medicine epitomizes what science can do. Today, more than 80% of our portfolio across small and large molecules has a precision medicine, or personalised healthcare approach. We have launched five diagnostic tests linked to our products in 2015 alone and by 2020, we aim for half our medicine launches to be paired with a diagnostic test. We will achieve this by continuing to apply scientific rigour and being open for collaboration; in this way, we believe we can unlock the potential of precision medicine to eliminate therapeutic guesswork and transform the lives of patients around the world. You can read the Insight here.